Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Inventory (2023 - 2025)

Iovance Biotherapeutics has reported Change in Inventory over the past 3 years, most recently at $4.0 million for Q4 2025.

  • Quarterly results put Change in Inventory at $4.0 million for Q4 2025, down 78.86% from a year ago — trailing twelve months through Dec 2025 was $14.2 million (down 67.98% YoY), and the annual figure for FY2025 was $14.2 million, down 67.98%.
  • Change in Inventory for Q4 2025 was $4.0 million at Iovance Biotherapeutics, up from $3.2 million in the prior quarter.
  • Over the last five years, Change in Inventory for IOVA hit a ceiling of $18.9 million in Q4 2024 and a floor of -$6.9 million in Q2 2025.
  • Median Change in Inventory over the past 3 years was $6.7 million (2024), compared with a mean of $6.2 million.
  • Biggest five-year swings in Change in Inventory: soared 2885.59% in 2024 and later tumbled 178.36% in 2025.
  • Iovance Biotherapeutics' Change in Inventory stood at $923000.0 in 2023, then skyrocketed by 1950.6% to $18.9 million in 2024, then tumbled by 78.86% to $4.0 million in 2025.
  • The last three reported values for Change in Inventory were $4.0 million (Q4 2025), $3.2 million (Q3 2025), and -$6.9 million (Q2 2025) per Business Quant data.